VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement [Yahoo! Finance]
VYNE Therapeutics Inc. (VYNE)
Company Research
Source: Yahoo! Finance
receptor (“TSHR”) antibody for Graves' disease (“GD”) and thyroid eye disease (“TED”) Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd (“GenSci”) Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028 Companies to hold conference call on December 17, 2025 at 8:30AM EDT NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”) and Yarrow Bioscience, Inc. (“Yarrow”) today announced that they have entered into a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction (the “Merger”). Upon completion of the Merger, the combined company expects to operate as Yarrow Bios
Show less
Read more
Impact Snapshot
Event Time:
VYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYNE alerts
High impacting VYNE Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
VYNE
News
- VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to ShareholdersBusiness Wire
- VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement GlobeNewswire
- Vitiligo Pipeline Market Report 2025: Comprehensive Insights About 18+ Companies and 20+ Pipeline Drugs - Emerging Therapies Like JAK Inhibitors Show Promise, Enhancing Treatment Options [Yahoo! Finance]Yahoo! Finance
- VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business UpdateGlobeNewswire
VYNE
Sec Filings
- 12/17/25 - Form 425
- 12/17/25 - Form 8-K
- 12/15/25 - Form 4
- VYNE's page on the SEC website